Loading clinical trials...

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice | Clinical Trials | Clareo Health

COMPLETED

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

A Multi-centre Prospective Non-interventional Study Investigating the Clinical Effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in Patients With Type 2 Diabetes Mellitus in a Real-world Setting

NCT04042441•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of the study is to collect information on how Ryzodeg® works in real world patients and to see if Ryzodeg® can lower blood sugar levels. Participants will get Ryzodeg® as prescribed to them by their doctor. The study will last for about 6 to 9 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol.
•The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before, and independently from, the decision to include the patient in this study.
•Male or female, age above or equal to 18 years at the time of signing informed consent.
•Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 26 weeks prior to signing informed consent.
•Available and documented HbA1c value for 12 weeks or less prior to signing informed consent.

Exclusion Criteria

•Hypersensitivity to the active substance or to any of the excipients as specified in the Ryzodeg® local label.
•Previous participation in this study. Participation is defined as signed informed consent.
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•Previous treatment with Ryzodeg®.

Locations (64)

Royal North Shore Hospital

St Leonards, New South Wales, Australia

Illawarra Diabetes Service Clinical Trials & Research Unit

Wollongong, New South Wales, Australia

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Mater Hospital Brisbane

South Brisbane, Queensland, Australia

Lyell McEwin Hospital

Elizabeth Vale, South Australia, Australia

South Australian Endocrine Research

Keswick, South Australia, Australia

Hobart Cardiology

Hobart, Tasmania, Australia

Box Hill Specialist Consulting rooms

Box Hill, Victoria, Australia

Baker IDI Heart and Diabetes Institute

Melbourne, Victoria, Australia

Rockingham General Hospital

Cooloongup, Western Australia, Australia

Key Dates

Start Date

July 29, 2019

Primary Completion Date

December 11, 2020

Completion Date

December 11, 2020

Last Updated

September 19, 2024

Enrollment

1,122

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Insulin Degludec/Insulin Aspart

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)